FDA grants priority review to odronextamab for R/R follicular lymphoma and R/R diffuse large B-cell lymphoma

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

In a move advertised as being in line with FDA’s goal of “radical transparency,” the agency July 10 announced the publication of more than 200 complete response letters.

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

Scientists at the Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus-driven lymphomas. The findings, published in the Journal of Medical Virology, demonstrate that these drugs, which work by blocking the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV’s ability to activate key cancer-promoting genes.

July 11, 2025

Vol.51 No.27

Podcast

In The Headlines: George Weiner on the importance of patients’ stories

In last week’s issue of The Cancer Letter, the cover story featured Col. Susan Fondy, an Army veteran and stage 3 breast cancer survivor, who is now living with lymphedema. Fondy is now a lymphedema advocate, working to prevent further cuts to the already-sparse funding for the disease.

July 09, 2025

Vol.51 No.26

Drugs & Targets

FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins

FDA has approved Zegfrovy (sunvozertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

July 03, 2025

Vol.51 No.26

Drugs & Targets

FDA grants accelerated approval to linvoseltamab-gcpt for r/r MM

FDA has granted accelerated approval to linvoseltamab-gcpt, trade name Lynozyfic, a bispecific B-cell maturation antigen-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

July 03, 2025

Vol.51 No.26

FDA grants priority review to odronextamab for R/R follicular lymphoma and R/R diffuse large B-cell lymphoma

YOU MAY BE INTERESTED IN

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

In The Headlines: George Weiner on the importance of patients’ stories

FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins

FDA grants accelerated approval to linvoseltamab-gcpt for r/r MM

Renew today!

Subscriber content

Never miss an issue!

Login

FDA grants priority review to odronextamab for R/R follicular lymphoma and R/R diffuse large B-cell lymphoma

YOU MAY BE INTERESTED IN

Rick and Mary Pazdur on facing “the other side of the stethoscope”A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

In The Headlines: George Weiner on the importance of patients’ stories

FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins

FDA grants accelerated approval to linvoseltamab-gcpt for r/r MM

Never miss an issue!

Login

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology